- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
CONTACT
Mary
Mary
 |
Tesamorelin is a peptide called growth hor-mone releasing factor (GHRF) that produces and propagates growth hor-mone in the body, helps to increase metabolism, reduce abdominal fat, improve body shape and use energy.
Tesamorelin is a synthetic growth ho-rmone releasing factor that promotes growth hor-mone pituitary secretion. This indirect method seems to maintain a more stable natural level, such as the C-J-C-1295 DAC. Clinical trials have shown that tasamorelin significantly reduces abdominal fat than human growth hor-mone itself has less side effects, although abdominal fat may be returned after Tesamorlein withdrawal.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.
Tesamorelin is a peptide called growth hor-mone releasing factor (GHRF) that produces and propagates growth hor-mone in the body, helps to increase metabolism, reduce abdominal fat, improve body shape and use energy.
Tesamorelin is a synthetic growth ho-rmone releasing factor that promotes growth hor-mone pituitary secretion. This indirect method seems to maintain a more stable natural level, such as the C-J-C-1295 DAC. Clinical trials have shown that tasamorelin significantly reduces abdominal fat than human growth hor-mone itself has less side effects, although abdominal fat may be returned after Tesamorlein withdrawal.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.
